Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>Ixodes scapularis</i> STING promotes Powassan virus infection in ticks.

Research square·2026
Same author

Editorial: Skin - confluence of vertebrate host defences, arthropod vectors, and vector-borne pathogens.

Frontiers in immunology·2025
Same author

Laboratory Management of Mammalian Hosts for <i>Ixodes scapularis</i> -Host-Pathogen Interaction Studies.

Comparative medicine·2024
Same author

Bacterial reprogramming of tick metabolism impacts vector fitness and susceptibility to infection.

Nature microbiology·2024
Same author

A ticking time bomb hidden in plain sight.

Science translational medicine·2023
Same author

Tick salivary glycans - a sugar-coated tick bite.

Trends in parasitology·2023

Related Experiment Video

Updated: Oct 13, 2025

Phage-Mediated Genetic Manipulation of the Lyme Disease Spirochete Borrelia burgdorferi
09:01

Phage-Mediated Genetic Manipulation of the Lyme Disease Spirochete Borrelia burgdorferi

Published on: September 28, 2022

2.3K

Hygromycin A in the Lymelight.

Paul Michael Arnaboldi1, Sukanya Narasimhan2

  • 1Department of Microbiology and Immunology, New York Medical College, Valhalla NY10595, USA; Biopeptides, Corp., East Setauket, NY 11733, USA.

Cell Host & Microbe
|November 11, 2021
PubMed
Summary

A novel antibiotic, Hygromycin A, shows promise for treating Lyme disease by targeting Borrelia burgdorferi. This spirochete-specific treatment preserves gut microbiome health, unlike current broad-spectrum antibiotics.

More Related Videos

Feeding of Ticks on Animals for Transmission and Xenodiagnosis in Lyme Disease Research
08:23

Feeding of Ticks on Animals for Transmission and Xenodiagnosis in Lyme Disease Research

Published on: August 31, 2013

13.4K
The Synergistic Effect of Visible Light and Gentamycin on Pseudomona aeruginosa Microorganisms
05:57

The Synergistic Effect of Visible Light and Gentamycin on Pseudomona aeruginosa Microorganisms

Published on: July 2, 2013

13.5K

Related Experiment Videos

Last Updated: Oct 13, 2025

Phage-Mediated Genetic Manipulation of the Lyme Disease Spirochete Borrelia burgdorferi
09:01

Phage-Mediated Genetic Manipulation of the Lyme Disease Spirochete Borrelia burgdorferi

Published on: September 28, 2022

2.3K
Feeding of Ticks on Animals for Transmission and Xenodiagnosis in Lyme Disease Research
08:23

Feeding of Ticks on Animals for Transmission and Xenodiagnosis in Lyme Disease Research

Published on: August 31, 2013

13.4K
The Synergistic Effect of Visible Light and Gentamycin on Pseudomona aeruginosa Microorganisms
05:57

The Synergistic Effect of Visible Light and Gentamycin on Pseudomona aeruginosa Microorganisms

Published on: July 2, 2013

13.5K

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Lyme disease, caused by Borrelia burgdorferi, is a growing public health concern.
  • Current treatments involve broad-spectrum antibiotics, which can negatively impact the gut microbiome.
  • There is a need for targeted therapies that are effective against Lyme disease while minimizing collateral damage to beneficial gut bacteria.

Purpose of the Study:

  • To evaluate the efficacy of Hygromycin A as a spirochete-specific antibiotic.
  • To assess the impact of Hygromycin A on the gut microbiome.
  • To explore Hygromycin A as a potential alternative treatment for Lyme disease.

Main Methods:

  • In vitro susceptibility testing of Borrelia burgdorferi against Hygromycin A.
  • In vivo studies to assess treatment efficacy and safety.
  • 16S rRNA sequencing to analyze gut microbiome composition before and after treatment.

Main Results:

  • Hygromycin A demonstrated potent activity against Borrelia burgdorferi.
  • The antibiotic exhibited spirochete specificity, with minimal impact on other bacterial species.
  • Treatment with Hygromycin A preserved the diversity and composition of the gut microbiome.

Conclusions:

  • Hygromycin A is a promising candidate for Lyme disease treatment due to its spirochete-specific action.
  • This targeted approach offers a potential advantage over broad-spectrum antibiotics by maintaining gut health.
  • Further research is warranted to fully establish Hygromycin A's therapeutic potential in Lyme disease management.